NOVOMEDIX LLC
- SAN DIEGO, CA 92126-6361
- novomedix.com (company website, opens in a new tab)
- Partnership or Limited Liability Partnership
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
- Women-Owned Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
NOVOMEDIX LLC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About NOVOMEDIX LLC
- Headquarters
- SAN DIEGO, CA 92126-6361
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIXQYMHKGDMU75
- CAGE4C2X1
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 13 awards
- Total awarded
- $10,613,686
- By phase
- SBIR Phase I: 9
- SBIR Phase II: 4
- By agency
- Department of Health and Human Services: 13
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 2
- 2024: 2
- 2022: 2
- 2021: 1
- 2019: 1
- 2016: 1
- 2012: 2
- 2010: 1
- 2007: 1
Awards (most recent first)
Arthrofibrosis control using small molecule inhibitors of interleukin-11
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $314,362
Sep 22, 2025 – Aug 31, 2026
Solicitation PA24-245 (2024) · Topic NIAMS
NOVOMEDIX TRANSITION TO PHASE II - THERAPEUTICS SBIR CONTRACTSBIR PHASE II - ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOLECULE
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $2,977,013
- Direct to Phase II
Solicitation 75N91024R00019 (2024) · Topic Transition PHII
Novel oral small molecules for progressive pulmonary fibrosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $306,872
Sep 20, 2024 – Feb 28, 2025
Solicitation PA23-230 (2023) · Topic NHLBI
Definitive (GLP) Toxicity and Toxicology Studies for a Novel Small Molecule for Protection Against Cardiotoxicity in Triple Negative Breast Cancer
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $500,000
Sep 15, 2024 – Aug 31, 2025
Solicitation PAR23-219 (2023) · Topic NHLBI
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $1,993,505
May 16, 2022 – Apr 30, 2024
- Direct to Phase II
Solicitation PA21-259 (2021) · Topic NHLBI
SBIR CONCEPT AWARD TO NOVOMEDIX- NOVEL SMALL MOLECULES FOR THE TREATMENT OF RHABDOMYOSARCOMA
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $355,000
Solicitation 75N91020R00043 (2021) · Topic NCICA22
Novel Therapy for Protection against Diabetes and its Complications in Ischemic Heart Disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $375,000
Sep 1, 2021 – Aug 31, 2022
Solicitation PA20-260 (2020) · Topic NHLBI
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $375,001
Sep 19, 2019 – Aug 31, 2020
Solicitation PA18-574 (2018) · Topic NHLBI
Novel antifibrotic small molecules for the treatment of heart failure
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $300,000
Apr 1, 2016 – Mar 31, 2018
Solicitation PA15-269 (2015) · Topic NHLBI
Development of novel small molecule drugs for the treatment of high risk B-ALL
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $300,000
Solicitation PA11-096 (2012) · Topic NCI · Research partner: Stub
The optimization of compounds that selectively inhibit protein synthesis for the
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2012 · $2,000,000
Solicitation PA11-096 (2012) · Topic NCI · Research partner: Stub
Optimization of compounds that selectively inhibit protein synthesis for the trea
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $300,236
Solicitation PHS2010-2 (2010) · Topic NCI
Discovery and Development of Compounds to Enhance b-cell Number and Function
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $516,697
Solicitation year 2007
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).
Socio-economic status
Self-represented in SAM.gov. WOSB and EDWOSB set-asides need SBA certification (13 CFR 127.300); SDVOSB and VOSB need SBA VetCert (13 CFR part 128). Confirm current certification before relying on it.
Learn more about small business set-asidesProduct & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with NOVOMEDIX LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.
